 Michelle Haas
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Latent Tuberculosis | 8 | 2021 | 67 | 3.100 |
Why?
| | Antitubercular Agents | 5 | 2024 | 200 | 1.060 |
Why?
| | Isoniazid | 3 | 2021 | 63 | 0.920 |
Why?
| | Tuberculosis | 3 | 2024 | 273 | 0.830 |
Why?
| | Tuberculin Test | 2 | 2024 | 36 | 0.750 |
Why?
| | Interferon-gamma Release Tests | 2 | 2024 | 32 | 0.740 |
Why?
| | Health Systems Plans | 1 | 2020 | 3 | 0.700 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 102 | 0.600 |
Why?
| | Directly Observed Therapy | 1 | 2018 | 15 | 0.600 |
Why?
| | Rifampin | 4 | 2021 | 85 | 0.510 |
Why?
| | Mass Screening | 2 | 2020 | 1149 | 0.510 |
Why?
| | Mycobacterium Infections | 1 | 2016 | 62 | 0.490 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2016 | 123 | 0.470 |
Why?
| | Mycobacterium tuberculosis | 1 | 2018 | 309 | 0.470 |
Why?
| | Receptors, CXCR5 | 1 | 2014 | 20 | 0.470 |
Why?
| | Lymphoid Tissue | 1 | 2014 | 67 | 0.450 |
Why?
| | Receptors, CXCR4 | 1 | 2014 | 83 | 0.450 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 232 | 0.420 |
Why?
| | Mycobacterium Infections, Nontuberculous | 3 | 2024 | 352 | 0.410 |
Why?
| | Nontuberculous Mycobacteria | 2 | 2024 | 203 | 0.390 |
Why?
| | HIV-1 | 2 | 2014 | 836 | 0.360 |
Why?
| | Drug Administration Schedule | 3 | 2021 | 768 | 0.320 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 1056 | 0.300 |
Why?
| | Emigrants and Immigrants | 2 | 2020 | 121 | 0.290 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 1040 | 0.270 |
Why?
| | HIV Infections | 2 | 2016 | 2719 | 0.220 |
Why?
| | Refugees | 1 | 2024 | 66 | 0.220 |
Why?
| | Anti-Infective Agents | 2 | 2015 | 248 | 0.190 |
Why?
| | Anti-Bacterial Agents | 4 | 2024 | 1708 | 0.180 |
Why?
| | Emigration and Immigration | 1 | 2020 | 49 | 0.170 |
Why?
| | Humans | 20 | 2024 | 129266 | 0.170 |
Why?
| | Tuberculin | 1 | 2019 | 8 | 0.160 |
Why?
| | Georgia | 1 | 2019 | 79 | 0.160 |
Why?
| | Single-Domain Antibodies | 1 | 2019 | 5 | 0.160 |
Why?
| | Caliciviridae Infections | 1 | 2019 | 17 | 0.160 |
Why?
| | Norovirus | 1 | 2019 | 23 | 0.150 |
Why?
| | United States | 5 | 2024 | 13826 | 0.150 |
Why?
| | Internal Medicine | 1 | 2020 | 241 | 0.150 |
Why?
| | Female | 13 | 2024 | 68551 | 0.140 |
Why?
| | Skin Diseases, Bacterial | 2 | 2015 | 21 | 0.140 |
Why?
| | Receptors, HIV | 2 | 2014 | 25 | 0.140 |
Why?
| | Nitrofurantoin | 1 | 2017 | 7 | 0.140 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2017 | 13 | 0.130 |
Why?
| | Cystitis | 1 | 2017 | 22 | 0.130 |
Why?
| | Retrospective Studies | 5 | 2021 | 14461 | 0.130 |
Why?
| | Drug Monitoring | 1 | 2018 | 216 | 0.130 |
Why?
| | Fluoroquinolones | 1 | 2017 | 45 | 0.130 |
Why?
| | Escherichia coli | 2 | 2019 | 766 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 339 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 333 | 0.120 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 27 | 0.120 |
Why?
| | Male | 11 | 2024 | 63512 | 0.120 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2016 | 135 | 0.120 |
Why?
| | Public Health | 1 | 2019 | 484 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2020 | 575 | 0.110 |
Why?
| | Adult | 7 | 2024 | 35495 | 0.110 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 37 | 0.110 |
Why?
| | Medication Therapy Management | 1 | 2015 | 72 | 0.110 |
Why?
| | Soft Tissue Infections | 1 | 2014 | 35 | 0.110 |
Why?
| | Infection Control | 1 | 2015 | 140 | 0.110 |
Why?
| | Immunophenotyping | 1 | 2014 | 310 | 0.100 |
Why?
| | Global Health | 1 | 2016 | 327 | 0.100 |
Why?
| | Drug Prescriptions | 1 | 2015 | 247 | 0.100 |
Why?
| | Cross Infection | 1 | 2015 | 217 | 0.100 |
Why?
| | Pediatrics | 1 | 2020 | 1049 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1365 | 0.100 |
Why?
| | Quality Improvement | 1 | 2020 | 1095 | 0.100 |
Why?
| | Anti-HIV Agents | 2 | 2016 | 754 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1481 | 0.100 |
Why?
| | Infant | 3 | 2020 | 8975 | 0.100 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 37 | 0.090 |
Why?
| | Middle Aged | 7 | 2024 | 31090 | 0.090 |
Why?
| | Receptors, CCR5 | 1 | 2011 | 57 | 0.090 |
Why?
| | CD4 Antigens | 1 | 2011 | 138 | 0.090 |
Why?
| | Internship and Residency | 1 | 2020 | 1047 | 0.090 |
Why?
| | HLA-DR Antigens | 1 | 2011 | 223 | 0.090 |
Why?
| | T-Lymphocyte Subsets | 1 | 2011 | 412 | 0.080 |
Why?
| | Membrane Glycoproteins | 1 | 2011 | 476 | 0.080 |
Why?
| | Patient Discharge | 1 | 2015 | 835 | 0.080 |
Why?
| | Lung Diseases | 2 | 2024 | 739 | 0.070 |
Why?
| | RNA, Viral | 1 | 2011 | 619 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2015 | 899 | 0.070 |
Why?
| | Child, Preschool | 3 | 2020 | 10459 | 0.070 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1688 | 0.070 |
Why?
| | Aged | 3 | 2021 | 22032 | 0.070 |
Why?
| | Adolescent | 4 | 2024 | 20313 | 0.070 |
Why?
| | Hospitalization | 1 | 2015 | 2052 | 0.060 |
Why?
| | Child | 3 | 2020 | 20785 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2020 | 7055 | 0.050 |
Why?
| | Program Evaluation | 2 | 2015 | 872 | 0.040 |
Why?
| | Travel | 1 | 2020 | 121 | 0.040 |
Why?
| | Blood Group Antigens | 1 | 2019 | 15 | 0.040 |
Why?
| | Capsid | 1 | 2019 | 90 | 0.040 |
Why?
| | Needs Assessment | 1 | 2020 | 359 | 0.040 |
Why?
| | Capsid Proteins | 1 | 2019 | 90 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2020 | 5736 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4406 | 0.040 |
Why?
| | Prevalence | 1 | 2024 | 2553 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2020 | 251 | 0.040 |
Why?
| | Crystallography, X-Ray | 1 | 2019 | 435 | 0.040 |
Why?
| | Treatment Failure | 1 | 2018 | 339 | 0.030 |
Why?
| | Epitopes | 1 | 2019 | 470 | 0.030 |
Why?
| | Cephalosporins | 1 | 2017 | 40 | 0.030 |
Why?
| | Young Adult | 2 | 2024 | 12391 | 0.030 |
Why?
| | Organizational Policy | 1 | 2017 | 79 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2017 | 175 | 0.030 |
Why?
| | Binding Sites | 1 | 2019 | 1250 | 0.030 |
Why?
| | Botswana | 1 | 2015 | 8 | 0.030 |
Why?
| | National Health Programs | 1 | 2015 | 17 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 1019 | 0.030 |
Why?
| | Time | 1 | 2015 | 75 | 0.030 |
Why?
| | Drug Utilization Review | 1 | 2015 | 57 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 2015 | 69 | 0.030 |
Why?
| | Population Surveillance | 1 | 2018 | 438 | 0.030 |
Why?
| | Inappropriate Prescribing | 1 | 2015 | 53 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5409 | 0.030 |
Why?
| | Community-Institutional Relations | 1 | 2015 | 95 | 0.030 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.030 |
Why?
| | Safety Management | 1 | 2015 | 112 | 0.030 |
Why?
| | Patient Care | 1 | 2015 | 108 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 248 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 978 | 0.030 |
Why?
| | Pneumonia, Bacterial | 1 | 2015 | 115 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2015 | 151 | 0.030 |
Why?
| | Drug Combinations | 1 | 2014 | 330 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2015 | 160 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2017 | 504 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 2120 | 0.030 |
Why?
| | Risk Assessment | 1 | 2020 | 3232 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1497 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2011 | 470 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2018 | 10202 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 9745 | 0.010 |
Why?
|
|
Haas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|